Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL · Alpha
██.█% Sign up free to reveal

Abbott Laboratories (ABT) AI Forecast

Our AI analyzed Abbott Laboratories. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$ABT Neutral Signal Full forecast available

Abbott Laboratories (ABT) Stock Forecast Sept. 24, 2026


Abbott Laboratories (ABT) AI Stock Price Forecast & Investment Analysis

Abbott Laboratories Stock Price Chart and Technical Analysis

Loading chart...

Abbott Laboratories (ABT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Abbott Laboratories's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Abbott Laboratories Investment Summary

When evaluating whether Abbott Laboratories (ABT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Abbott Laboratories (ABT) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $180 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Abbott Laboratories's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Abbott Laboratories along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Abbott Laboratories is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Abbott Laboratories

Sign Up Free
Corporate Identity

Abbott Laboratories (Stock Symbol: ABT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the NYSE exchange.

Leadership & Workforce

Detailed information about Abbott Laboratories's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Abbott Laboratories...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Abbott Laboratories...

Unlock Full Company Profile

Get complete details about Abbott Laboratories

Sign Up Free
Revenue & Growth Analysis

Abbott Laboratories generates annual revenues of $45 billion , demonstrating substantial market presence and operational scale.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Abbott Laboratories...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Abbott Laboratories...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Abbott Laboratories...

Unlock Financial Analysis

Get complete financial metrics for Abbott Laboratories

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Abbott Laboratories's AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Abbott Laboratories strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Abbott Laboratories competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company demonstrates exceptional operational efficiency through free cash flow generation of $7 billion annually , with year-over-year cash flow growth of 5.7%. This substantial cash generation capability provides significant strategic flexibility for acquisitions, share repurchases, dividend growth, or debt reduction—all while maintaining operational investments necessary to defend market position.

Margin & Pricing Power Analysis

The company maintains a 56.3% gross margin indicating healthy pricing power relative to direct production costs. This margin level suggests the company has successfully differentiated its products or services, allowing it to command prices meaningfully above input costs. Maintaining these margins requires ongoing investment in brand, technology, or other differentiating factors.

Operating margin of 17.1% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This healthy operating margin shows balanced investment in growth functions while maintaining reasonable profitability.

Asset Utilization Efficiency

Asset turnover ratio of 0.41x indicates moderate asset turnover. Lower turnover is expected where the business model requires significant infrastructure, so the ratio should be read against the company's own industry.

Financial Strength & Leverage

Current ratio of 1.39 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Abbott Laboratories (ABT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Abbott Laboratories stock analysis.

Deep dive into Abbott Laboratories's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Abbott Laboratories stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Abbott Laboratories: With a P/E ratio of 28.58, the market highly values future growth prospects.

P/E Ratio 28.58x
P/B Ratio 3.45x
Market Cap $180.26B
Dividend Yield 2.33%
EPS $3.57
Book Value/Share $30.04
Revenue/Share $25.91
FCF/Share $4.24
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Abbott Laboratories converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Abbott Laboratories: An ROE of 12.1% shows good shareholder value creation.

ROE 12.1%
ROA 5.7%
ROIC 8.4%
Gross Margin 56.3%
Operating Margin 17.1%
Net Margin 13.9%
EBT Margin 18.0%
Tax Rate 22.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Abbott Laboratories's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Abbott Laboratories: A current ratio of 1.39 shows adequate liquidity.

Current Ratio 1.39x
Quick Ratio 1.01x
D/E Ratio 1.11x
Financial Leverage 2.12x
Interest Coverage 4.1x
Working Capital $7.13B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Abbott Laboratories's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Abbott Laboratories: Free cash flow of $7378M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $9.46B
Free Cash Flow $7.38B
Capital Spending -$2.09B
OCF Growth YoY 5.7%
FCF Growth YoY 10.8%
FCF/Sales 16.4%
CapEx/Sales 4.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Abbott Laboratories uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Abbott Laboratories: An asset turnover of 0.41x suggests room for improvement in asset utilization.

Asset Turnover 0.41x
Receivables Turnover 5.5x
Inventory Turnover 2.8x
Fixed Assets Turnover 3.7x
Days Sales Outstanding 66 days
Days Inventory 129 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Abbott Laboratories's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Abbott Laboratories: With annual revenue of $45134M, Abbott Laboratories operates at significant scale.

Income Statement
Total Revenue $45.13B
Operating Income $7.71B
Net Income $6.28B
R&D Expense $2.99B
SG&A Expense $13.01B
Cost of Goods Sold $19.74B
Balance Sheet Highlights (USD millions)
Total Current Assets $25.51B (23.1% of assets)
Cash & Short-term Investments $6.80B (6.2% of assets)
Accounts Receivable $8.21B (7.4% of assets)
Inventory $6.99B (6.3% of assets)
Total Liabilities $57.73B (52.3% of assets)
Dividend & Shareholder Information
Dividends Per Share $2.42
Payout Ratio 67.8%
Shares Outstanding 1742M

Latest Abbott Laboratories Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Abbott Laboratories (ABT) stock price and investment outlook.

📰 Loading...

Where ABT sits on the market map

Explore the map →

Abbott Laboratories Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Abbott Laboratories (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
ABT ██% $180.26B 28.6x 3.5x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Abbott Laboratories Stock Forecast

How accurate are Abbott Laboratories stock predictions?

A per-ticker accuracy statistic for ABT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Abbott Laboratories stock price forecasts?

Our analysis considers Abbott Laboratories's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Abbott Laboratories a good investment in 2026?

Based on our AI analysis, Abbott Laboratories shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Abbott Laboratories forecasts updated?

Abbott Laboratories forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Abbott Laboratories?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...